Survival RateNon-Small Cell Lung CancerLung canceris the most common cause of death from oncological diseases all over the world.Primary treatment of patients with the early stage of non-small cell lungcancer is a surgery. However, after surgery 30% - 85% of patients undergodisease progre......
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent kind of lung cancer with around 85% of total lung cancer cases. Despite vast therapies being available, the survival rate is low (5 year survival rate is 15%) making it essential to comprehend the mechanism for NSCLC cell survival a...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose...
Small Cell Lung Cancer Small cell lung cancer, also called oat cell lung cancer, accounts for about 10% of all lung cancers. This form of cancer tends to spread quickly. Lung Cancer Stages: 0-4 After the type of lung cancer is determined, the type is then assigned a lung cancer stage...
In the decade since the last Lancet Seminar on lung cancer there have been advances in many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (NSCLC). An international panel of experts has been brought together to focus on changes in the epidemiology and pat...
The 5-year survival rate of non-small cell lung cancer (NSCLC) patients is very low. MicroRNAs (miRNAs) are involved in the occurrence of NSCLC. miR-122-5p interacts with wild-type p53 (wtp53), and wtp53 affects tumor growth by inhibiting the mevalonate (MVA) pathway. Therefore, this ...
non–small cell lung cancerolder adultspembrolizumabprognosissurvivalBackground Limited data exist regarding the characteristics and survival outcomes of older adults with non–small cell lung cancer (NSCLC) who receive immune checkpoint inhibitors in routine oncology practice. Methods Using the Surveillance,...
Approximately 80% of lung cancers is non-small cell lung cancer (NSCLC), and 5-year survival rate of the disease is ~ 20%. On the other hand, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology. IPF is refractory to treatment and has...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death worldwide1,2,3. Despite more recent therapeutic advances, outcomes remain poor, with a 10-year survival rate of only 5%4. NSCLC shows a relatively low degree of tumour cell purity compared to other tumours, with ...